Johns Hopkins: Study Suggests Side-Effects And Costs Are Biggest Issues For Users Of HIV Pre-Exposure Prophylaxis
February 01, 2023
February 01, 2023
BALTIMORE, Maryland, Feb. 1 (TNSjou) -- Johns Hopkins University's Bloomberg School of Public Health issued the following news release:
* * *
Respondents preferred long-acting injectable PrEP, which came to market in early 2022, over short-acting pills
* * *
A new survey finds that men who would be potential users of HIV pre-exposure prophylaxis (PrEP) medication prefer long-acting injections over pills, but rank side effects and costs as . . .
* * *
Respondents preferred long-acting injectable PrEP, which came to market in early 2022, over short-acting pills
* * *
A new survey finds that men who would be potential users of HIV pre-exposure prophylaxis (PrEP) medication prefer long-acting injections over pills, but rank side effects and costs as . . .